Company Overview of Biotie Therapies AG
Biotie Therapies AG provides drug development services focusing on neurology and psychiatry. Its SYN-118 product is a therapy for advanced Parkinson's disease patients. The company also provides clinical development programs and research services. It has a strategic partnership with UCB SA. The company was formerly known as Synosia Therapeutics AG and changed its name to Biotie Therapies AG in February 2011. The company was founded in 2005 and is based in Basel, Switzerland. As of February 2, 2011, Biotie Therapies AG operates as a subsidiary of Biotie Therapies Corp.
Founded in 2005
41 61 206 92 02
41 61 206 92 01
Key Executives for Biotie Therapies AG
Similar Private Companies By Industry
|AC Immune SA||Europe|
|Acino Holding AG||Europe|
|Albea Pharmaceuticals AG||Europe|
|Alpen Pharma AG||Europe|
|Alpex Pharma SA||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|Bloomberg L.P.||United States|
Sponsored Financial Commentaries
To contact Biotie Therapies AG, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.